Condition
Critical Illness Polyneuromyopathy
Total Trials
6
Recruiting
1
Active
2
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Completed4
Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06419699Active Not Recruiting
CPAx: Responsiveness and Minimal Clinically Important Difference
NCT07478367RecruitingPrimary
Critical Illness Weakness Outside the Intensive Care Unit.
NCT04423796Not ApplicableCompletedPrimary
Robotic Assisted Early Mobilization in Ventilated ICU Patients
NCT04750265Not ApplicableCompleted
Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19
NCT04435080Completed
Physical Rehabilitation in ICU in ARDS Patients With COVID-19
NCT04227548Not ApplicableCompletedPrimary
Reference Values for Compound Muscle Action Potential Amplitude Obtained by Direct Muscle Stimulation
Showing all 6 trials